Our Services
Spravato: a breakthrough for treatment-resistant depression.
FDA-approved esketamine nasal spray.
Spravato (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression or major depressive disorder with suicidal ideation. It works differently than traditional antidepressants and is administered in our clinic under medical supervision.
How Spravato works
Spravato is a nasal spray that you self-administer under the supervision of our clinical team. It is derived from ketamine and targets the glutamate system in the brain, promoting new neural connections and potentially rapid symptom improvement.
Treatment sessions are conducted in our clinic. You will self-administer the nasal spray and then rest comfortably in a private room while our team monitors you for approximately 2 hours. Sessions are typically scheduled twice weekly for the first month, then weekly or biweekly.
Because Spravato is FDA-approved and available through a restricted distribution program (REMS), it is covered by many insurance plans, making it a more accessible option than IV ketamine for many patients.
“Spravato gives us an FDA-approved option specifically designed for treatment-resistant depression. Being able to offer this in a comfortable, supervised setting makes a real difference for our patients.”
Elizabeth Elwood, PMHNP-BC
Clinical Director, Waybridge Clinics
The evidence
Spravato by the numbers
Spravato (esketamine) is the first FDA-approved nasal spray for treatment-resistant depression, with strong clinical trial evidence.
FDA
Approved for treatment-resistant depression
FDA approval March 2019
2x
More likely to respond vs. switching antidepressants
TRANSFORM-2 clinical trial, Popova et al., 2019
51%
Reduction in relapse risk with continued treatment
SUSTAIN-1 trial, Daly et al., AJP 2019
Benefits
Why patients choose this treatment
- FDA-approved for treatment-resistant depression
- Self-administered nasal spray (simple to use)
- Monitored in a comfortable clinical setting
- Often covered by insurance
- Can produce improvement faster than traditional antidepressants
- Works through a different mechanism than standard medications
Conditions Treated
This treatment may help with
Insurance Note
Spravato is covered by most major insurance plans. Our team handles the prior authorization process and will verify your benefits before treatment begins.
Common Questions
Frequently asked questions
What is the difference between Spravato and IV ketamine?+
Spravato is an FDA-approved nasal spray containing esketamine (a derivative of ketamine). Because it is FDA-approved, it is typically covered by insurance. IV ketamine uses the full ketamine molecule delivered intravenously, which tends to be cash-pay. Both can be effective, and your provider will help determine which is best for you.
How long does each session take?+
Plan for approximately 2.5 hours per session. The nasal spray administration takes about 5-10 minutes, followed by a 2-hour monitoring period in our comfortable treatment room.
What are the side effects?+
Common side effects include temporary dissociation, dizziness, nausea, and increased blood pressure during the monitoring period. These effects typically resolve before you leave the clinic.
Can I drive after a Spravato session?+
No. You must not drive or operate machinery for the rest of the day after each treatment. Please arrange for someone to pick you up from your appointment.
How do I know if I qualify for Spravato?+
Spravato is approved for patients who have not responded adequately to at least two different antidepressant treatments. Our team can help determine if you meet the criteria.
Think Spravato might be right for you?
Schedule a free consultation. Our team will assess your eligibility and handle the insurance authorization.
Schedule a Free Call